Alendronate Administration and Dosing Guidelines for Osteoporosis

Administration Instructions

The American College of Endocrinology and the American Association of Clinical Endocrinologists advise that alendronate should be taken on an empty stomach first thing in the morning with a full glass (6–8 oz) of plain water, and the patient must remain upright for at least 30 minutes before consuming any food, beverages, or other medications. 1, 2
The medication must be taken immediately after arising following an overnight fast, and at least 30 minutes (some sources 30–60 minutes) should elapse before ingesting anything other than plain water. 1, 2
The tablet should be swallowed whole with only plain water; mineral water, coffee, orange juice, or other beverages reduce absorption by roughly 60 %. 1, 2
Patients must stay standing or sitting for a minimum of 30 minutes after ingestion to avoid esophageal irritation. 1, 2
Non‑adherence to these requirements markedly lowers drug absorption and raises the risk of esophageal irritation. 1, 2

The standard therapeutic dose for treatment of osteoporosis is 70 mg once weekly (most commonly used) and is therapeutically equivalent to 10 mg daily. 1, 2
For primary prevention in post‑menopausal women, a weekly dose of 35 mg or a daily dose of 5 mg may be used. 3, 4

Alendronate should not be prescribed to patients with esophageal abnormalities that delay tablet transit (e.g., achalasia, strictures, dysmotility). 1, 2
It is contraindicated in individuals unable to remain upright (standing or sitting) for at least 30 minutes after dosing. 1, 2, 3, 4
Patients who cannot reliably follow the dosing instructions are unsuitable candidates. 1, 2
Active hypocalcemia must be corrected before initiating therapy. 1, 2, 5
A creatinine clearance below 35 mL/min is an absolute contraindication. 1, 2, 5
Active upper gastrointestinal disease or conditions causing malabsorption (e.g., gastric bypass, celiac disease, Crohn’s disease) preclude use. 1, 2

Vitamin D deficiency should be corrected (target 25‑OH‑D ≥ 30 ng/mL) to prevent bisphosphonate‑related hypocalcemia. 6, 7, 8
Adequate calcium intake (≈ 1200 mg daily from all sources) should be ensured. 8
Vitamin D supplementation of 800–1000 IU daily is recommended. 8
Creatinine clearance must be calculated using the Cockcroft‑Gault formula with actual body weight. 1, 2
Vitamin D repletion can be achieved with ergocalciferol 50,000 IU weekly for 8 weeks before starting alendronate, especially when intravenous bisphosphonates are considered. 6, 7, 8

Renal impairment: No dose adjustment is required for patients with creatinine clearance between 35–60 mL/min, but alendronate is not recommended for clearance < 35 mL/min. 1, 2, 5
Hepatic impairment: No dose adjustment is necessary because alendronate is neither metabolized nor excreted in bile. 2

Consuming food, coffee, or other beverages with the tablet reduces absorption by up to 60 %. 2
Lying down within 30 minutes of dosing increases the risk of esophageal irritation. 1, 2
Initiating therapy without correcting hypocalcemia or vitamin D deficiency raises the risk of severe hypocalcemia. 6, 7, 8
Prescribing alendronate to patients with esophageal disorders or who cannot remain upright markedly increases the likelihood of serious esophageal complications. 1, 2, 8

Delayed‑release risedronate (Atelvia) may be taken with or after food and can be considered for patients with upper gastrointestinal problems, although its incidence of upper GI adverse events is not lower than that of conventional alendronate. 1, 2